Compare OXBR & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXBR | ICU |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | Cayman Islands | United States |
| Employees | 3 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 9.1M |
| IPO Year | N/A | N/A |
| Metric | OXBR | ICU |
|---|---|---|
| Price | $0.94 | $2.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 8.8K | ★ 51.2K |
| Earning Date | 04-06-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $497.99 | $1,043.70 |
| Revenue Next Year | $42.14 | $54.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $0.22 |
| 52 Week High | $2.85 | $2.98 |
| Indicator | OXBR | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 36.94 |
| Support Level | $0.76 | $0.56 |
| Resistance Level | $1.46 | $2.85 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 53.57 | 2.98 |
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.